DARA Biosciences — Investor Presentation (October 2013)
32 slides from DARA Biosciences's investor presentation, Oct 29, 2013
Slide 1: Corporate Presentation October 2013
NASDAQ: DARA www.darabio.com Corporate Presentation October 2013
Slide 2: Forward Looking Statements
Page * Page * Forward Looking Statements All statements in this presentation that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended , and are subject to risks and uncertainties. These statements are based on the current expectatio
Slide 3: Overview
Overview DARA is building to be a leader in the oncology/supportive care market with a comprehensive portfolio of synergistic products • Complemented existing product portfolio through agreement with Mission Pharmacal* Current ─ Soltamox® ─ Gelclair® ─ Bionect® New (1) ─ Binosto® ─ Ferralet® 90 ─ Aq
Slide 4: Pipeline
Preclinical Phase 1 Phase 2 Phase 3 NDA Approved Pipeline * Through shared sales force agreement with Mission Pharmacal COMMERCIAL PIPELINE Soltamox® (oral liquid tamoxifen citrate) for breast cancer Bionect® (hyaluronic acid) for burns and skin changes from radiation Gelclair® (hyaluronic acid oral
Slide 5: Why oncology supportive care?
Page * Why oncology supportive care? • Significant commercial opportunity o Each product addresses unmet medical need ─ Competitive products not optimal o Growth potential ─ Expand into other supportive care areas • Unique positioning for DARA in the specialty pharma market o Establish a leadership
Slide 6: Oncology Supportive Care product areas
Osteoporosis Anemia Oral mucositis Dry mouth CCIPN* Soltamox® * Phase 2b - ready drug (KRN5500). Chronic chemotherapy induced peripheral neuropathy (CCIPN) Soltamox®
Slide 7: Product Synergy
DARA can leverage its newly established portfolio of oncology supportive care products* Page * Potential for synergistic portfolio use in the same patient Product Synergy Breast cancer patient (illustrative) • Soltamox® • Bionect® • Gelclair® • Ferralet® 90 • Binosto® • Aquoral® ─ Breast cancer * Ba
Slide 8: Soltamox®: Exclusive US license from Rosemont Pharmaceuticals
Exclusive US license from Rosemont Pharmaceuticals, UK. Soltamox®
Slide 9: Soltamox® Breast Cancer Overview
Soltamox® • Breast cancer is the second leading cause of cancer mortality in women ◦ 2.6 million women in the US with breast cancer history ◦ Approximately 230,000 are newly diagnosed each year • Tamoxifen is widely used ◦ Receptor-positive breast cancer (approximately 80% of all cases) ◦ Used as a
Slide 10: Soltamox® (tamoxifen citrate)
Soltamox® (tamoxifen citrate)* Soltamox® is the only FDA approved patent protected oral liquid formulation of tamoxifen • Once daily/convenient to use • Bioequivalent to tamoxifen tablet o Approved as a 505(b)(2) ─ Not substitutable • Choice/option offered to all tamoxifen patients • Patients who do
Slide 11: Gelclair®: Exclusive US license from Helsinn Pharmaceuticals
Exclusive US license from Helsinn Pharmaceuticals, Switzerland Gelclair®
Slide 12: Oral mucositis overview
With the advent of effective treatment for chemotherapy- induced nausea and vomiting (CINV), “mucositis has now emerged as the most significant adverse symptom of cancer therapy reported by patients.” (1) Oral mucositis overview • Oral mucositis is damage to the oral mucosa (open sores) commonly due
Slide 13: Oral mucositis ranked among chemotherapy side effects
Oral mucositis Ranked Assessment of Chemotherapy Side Effects of Patients with Ovarian Cancer Patients Regard Oral Mucositis As A Major Problem, Secondary Only to Chemotherapy Induced Nausea and Vomiting (CINV) (1)
Slide 14: Gelclair®
Gelclair® * Gelclair® is a patent protected oral bioadherent gel (mouthwash) creating a protective film with fast pain relief • Convenient/easy to use • Hyaluronic acid based - may aid healing • Improvement in quality of life o Eat and drink normally o Speech o Sleep Ø Gelclair® could offer meaningf
Slide 15: The Action Of Gelclair® On Oral Mucositis
Page * Without With Inflammation around nerve endings - overstimulation Gelclair coating The key ingredients of Gelclair form a protective film over the oral mucosa, which shields the exposed nerve endings from over-stimulation for up to 5 to 7 hours. Oral Mucositis generates pain and induces patien
Slide 16: Gelclair® packets
Gelclair® Gelclair® packets are simple and convenient to use!
Slide 17: Bionect®: Marketing agreement from Innocutis Pharmaceuticals
* Marketing agreement from Innocutis Pharmaceuticals, US Bionect® *
Slide 18: Bionect® radiation dermatitis overview
Bionect® Radiation dermatitis is a side effect of cancer radiation treatment and causes inflammation of the skin • Red/itchy/peeling/blistering • Mild cases- “sunburn” like Approximately 85% of cancer patients on radiation will experience skin reaction/damage (1) • 150,000 annual prescriptions • Mos
Slide 19: Bionect®
Bionect® * Bionect® is a patent protected cream/gel LMW-HA to treat burns/skin changes associated with radiation treatment • LMW formulation allows for penetration to hydrate the dermal matrix o Helps resolve inflammation o Prophylactic use shown to postpone signs of acute epithelitis o Continued us
Slide 20: Treated with HMW-HA vs LMW-HA
Treated with HMW-HA Treated with LMW-HA oon Ane Fsvidemi Increase in Microbial Organisms. Pilosebaceous. Unit Dermis Dermal Matrox Degeneration ‘Macrophages s * % : ie
Slide 21: Hyaluronic Acid Reduces Skin Reactions to Radiotherapy
Liguori et al., 1997 n = 70 (HA) n = 64 (placebo) P: < 0.0006 < 0.0001 < 0.0001 0.0002 0.0353 % of patients with skin status score > 1 is lower with HA Hyaluronic Acid Reduces Skin Reactions to Radiotherapy Bionect®
Slide 22: Complementary Supportive Care Products
Complementary Supportive Care Products* • Binosto® (alendronate sodium) o Innovative treatment for osteoporosis o Once-weekly o Easy oral effervescent administration (strawberry) • Ferralet® 90 (anemia-iron supplement) o Unique patented blend of 2 different forms of iron o Once daily • Aquoral® (lip
Slide 23: Ferralet 90 and Binosto product materials
Oral iron therapy that Delivers es ‘Drea | (9059-553 OF weenie“ For the teament of ima deficiency Introducing a welcome innovation in ‘osteoporosis therapy
Slide 24: Sales Force Expansion
• Increased reach and frequency on highest prescribing oncologists • Expansion to 20 national sales representatives (from 5) contracted with ALAMO Pharma Services o Fully operational late December 2013 Partnership with ALAMO ideally complements DARA • Full service provider o Infrastructure/SFA o Tim
Slide 25: National sales coverage
Page * National sales coverage
Slide 26: KRN5500: A Novel Phase 2b Drug
KRN5500: A Novel Phase 2 Drug DARA’s clinical development compound targets painful CCIPN* • Area of significant unmet medical need o Existing approved therapies are ineffective • Impressive Phase 2a clinical results • “Fast track” status from FDA • Seeking Orphan designation * chronic chemotherapy i
Slide 27: What makes KRN5500 so exciting?
KRN5500: A Novel Phase 2 Drug What makes KRN5500 so exciting? • Non-opioid • Rapid onset - prolonged duration • Statistically significant results in a small clinical trial of refractory patients (vs. placebo) o 24% reduction of pain (p=0.03) o 29.5% median maximal reduction (p=0.02) o 83% clinically
Slide 28: KRN5500 Phase 2a Primary Endpoint
KRN5500 Phase 2a Primary Endpoint N = 7 7 6 6 4 4 2 2 2 2 2 7 N = 12 12 12 10 10 7 7 6 5 3 3 12 • Primary Endpoint = median Clinic NRS scores 1 week after final dose • KRN5500 24%; Placebo 0% • p=0.03 (Wilcoxon Rank Sum Test) KRN5500 reduces median target pain intensity 24%: placebo 0% (p=0.03) KRN5
Slide 29: Capitalization Summary
Cash (as of 6-30-13) $4.9 million Debt None Common Outstanding Shares (1) 31.5 million Warrants (weighted average price of $1.54) 19.8 million Options (weighted average price of $1.08) (2) 3.4 million Fully Diluted Shares Outstanding 54.7 million Capitalization Summary Source: Company’s Internal Dat
Slide 30: Anticipated Key Events
Multiple anticipated key events expected to continue to build momentum Anticipated Key Events • Expanded national sales organization (Mission/Alamo) - Q1 • Commercial rollout - ongoing • Potential KRN5500 orphan designation - ongoing • Development partner for KRN5500 and initiate Phase 2b • In-licen
Slide 31: DARA - Summary
DARA - Summary DARA represents a compelling investment opportunity with potential for near and long term value creation and revenue growth • Unique strategic positioning with a portfolio of synergistic oncology supportive care products • Expanded sales force with an experienced/successful CSO • Nove
Slide 32: www.darabio.com
NASDAQ: DARA www.darabio.com Corporate Presentation October 2013 Rev. 1029
DARA BioSciences — Investor Presentation (October 2013) on 6ix